No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 29 of the 40 quarters in the window, leaving 11 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 77.0x · 10Y median 89.6x · 46th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:23:02.571Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Ocugen, Inc. (OCGN) stock was $1.04 as of Oct 6, 2026, 4:00 PM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months -41.1% · 3-year avg +36.0%/yr · 5-year avg -31.6%/yr
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness.
Biotechnology · Malvern, PA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.06
Revenue Est.
$1.32M
Last Quarter Results
EPS
$-0.06
vs Estimate
$-0.05
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OCGN | $352.67M | $1.04 | +0.00% | -41.09% | -31.57% | -40.73% | N/A |
| 2EMBC | $353.00M | $5.95 | +1.19% | -57.42% | N/A | N/A | vs OCGN |
| 3ENTA | $353.88M | $12.17 | -3.41% | +21.86% | -26.94% | -7.11% | vs OCGN |
| 4VMD | $355.36M | $9.33 | +0.97% | +33.15% | +10.93% | N/A | vs OCGN |
| 5ARTV | $355.43M | $7.27 | +1.96% | +140.68% | N/A | N/A | vs OCGN |
| 6OBIO | $349.70M | $5.84 | -3.15% | +121.66% | -9.35% | N/A | vs OCGN |
N/A
$1.49M
vs Estimate
$888833.00
Consensus Rating
Based on 6 analysts
Average Price Target
$12.17
+1069.9% upside
Low
$8.00
Current
$1.04
High
$22.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.07 | $-0.06 | $-0.04 | 3 |
| Quarter ending Dec 2026 | $-0.08 | $-0.07 | $-0.04 | 3 |
| Quarter ending Mar 2027 | $-0.10 | $-0.08 | $-0.07 | 1 |
| Quarter ending Jun 2027 | $-0.10 | $-0.08 | $-0.07 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.28 | $-0.26 | $-0.22 | 4 |
| FY 2027 | $-0.35 | $-0.27 | $-0.19 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.27M | $1.32M | $1.36M | 3 |
| Quarter ending Dec 2026 | $1.09M | $1.26M | $1.49M | 4 |
| Quarter ending Mar 2027 | $1.04M | $1.20M | $1.42M | 2 |
| Quarter ending Jun 2027 | $2.08M | $2.40M | $2.83M | 2 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.02M | $4.96M | $5.71M | 5 |
| FY 2027 | $4.89M | $7.33M | $9.78M | 3 |
